Relative roles of various efflux pathways in net cholesterol efflux from macrophage foam cells in atherosclerotic lesions

Current Opinion in Lipidology

Volumn 21, Issue 5, 2010, Pages 441-453

  Zhao, Ying ^a   Van Berkel, Theo J C ^a   Van Eck, Miranda ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

aqueous diffusion; ATP binding cassette A1; ATP binding cassette G1; HDL; scavenger receptor class B type I

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; CHOLESTEROL; CYTOKINE; HIGH DENSITY LIPOPROTEIN; LIPID; SCAVENGER RECEPTOR BI;

ATHEROSCLEROSIS; CELL TRANSPORT; CHOLESTEROL TRANSPORT; DIABETES MELLITUS; DIFFUSION; FOAM CELL; HUMAN; HYPOXIA; INFLAMMATION; MACROPHAGE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CHOLESTEROL; FOAM CELLS; HUMANS; PLAQUE, ATHEROSCLEROTIC; RECEPTORS, SCAVENGER;

EID: 77957569778     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32833dedaa     Document Type: Review

References (158)

1. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol tranport. J Lipid Res 1995; 36:211-228.
2. Cavelier C, Rohrer L, von Eckardstein A. ATP-binding cassette transporter A1 modulates apolipoprotein A-I transcytosis through aortic endothelial cells. Circ Res 2006; 99:1060-1066.
3. Rohrer L, Ohnsorg PM, Lehner M, et al. High-density lipoprotein transport through aortic endothelial cells involves scavenger receptor BI and ATPbinding cassette transporter G1. Circ Res 2009; 104:1142-1150.
4. Rothblat GH, Phillips MC. High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr Opin Lipidol 2010; 21:229-238.
5. Davidson WS, Sparks DL, Lund-Katz S, Phillips MC. The molecular basis for the difference in charge between prebeta- and alpha-migrating high density lipoproteins. J Biol Chem 1994; 269:8959-8965.
6. Kunitake ST, La Sala KJ, Kane JP. Apolipoprotein A-I-containing lipoproteins with prebeta electrophoretic mobility. J Lipid Res 1985; 26:549-555.
7. Phillips MC, Johnson WJ, Rothblat GH. Mechanisms and consequences of cellular cholesterol exchange and transfer. Biochim Biophys Acta 1987; 906:223-276.
8. Rothblat GH, PhillipsMC. Mechanismof cholesterol efflux fromcells. Effects of acceptor structure and concentration. J Biol Chem 1982; 257:4775-4782.
9. Klucken J, Buchler C, Orso E, et al. ABCG1 (ABC8), the human homolog of the Drosophila white gene, is a regulator of macrophage cholesterol and phospholipid transport. Proc Natl Acad Sci U S A 2000; 97:817-822.
10. Yancey PG, Llera-Moya M, Swarnakar S, et al. High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI. J Biol Chem 2000; 275:36596-36604.
11. Mulya A, Lee JY, Gebre AK, et al. Minimal lipidation of prebeta HDL by ABCA1 results in reduced ability to interact with ABCA1. Arterioscler Thromb Vasc Biol 2007; 27:1828-1836.
12. Van EM, Pennings M, Hoekstra M, et al. Scavenger receptor BI and ATPbinding cassette transporter A1 in reverse cholesterol transport and atherosclerosis. Curr Opin Lipidol 2005; 16:307-315
13. Calvo D, Gomez-Coronado D, Lasuncion MA, Vega MA. CLA-1 is an 85-kD plasma membrane glycoprotein that acts as a high-affinity receptor for both native (HDL, LDL, and VLDL) and modified (OxLDL and AcLDL) lipoproteins. Arterioscler Thromb Vasc Biol 1997; 17:2341-2349.
14. Ahras M, Naing T, McPherson R. Scavenger receptor class B type I localizes to a late endosomal compartment. J Lipid Res 2008; 49:1569-1576.
15. Gu X, Kozarsky K, Krieger M. Scavenger receptor class B, type I-mediated [3H]cholesterol efflux to high and low density lipoproteins is dependent on lipoprotein binding to the receptor. J Biol Chem 2000; 275:29993-30001.
16. De La Llera-Moya M, Rothblat GH, Connelly MA, et al. Scavenger receptor BI (SR-BI) mediates free cholesterol flux independently of HDL tethering to the cell surface. J Lipid Res 1999; 40:575-580.
17. Kellner-Weibel G, de La Llera-Moya M, Connelly MA, et al. Expression of scavenger receptor BI in COS-7 cells alters cholesterol content and distribution. Biochemistry 2000; 39:221-229.
18. Connelly MA, De La Llera-Moya M, Peng Y, et al. Separation of lipid transport functions by mutations in the extracellular domain of scavenger receptor class B, type I. J Biol Chem 2003; 278:25773-25782.
19. Pagler TA, Rhode S, Neuhofer A, et al. SR-BI-mediated high density lipoprotein (HDL) endocytosis leads to HDL resecretion facilitating cholesterol efflux. J Biol Chem 2006; 281:11193-11204.
20. Pagler TA, Neuhofer A, Laggner H, et al. Cholesterol efflux via HDL resecretion occurs when cholesterol transport out of the lysosome is impaired. J Lipid Res 2007; 48:2141-2150.
21. Hirano K, Yamashita S, Nakagawa Y, et al. Expression of human scavenger receptor class B type I in cultured human monocyte-derived macrophages and atherosclerotic lesions. Circ Res 1999; 85:108-116.
22. Yu L, Cao G, Repa J, Stangl H. Sterol regulation of scavenger receptor class B type I in macrophages. J Lipid Res 2004; 45:889-899.
23. Chinetti G, Gbaguidi FG, Griglio S, et al. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 2000; 101:2411-2417.
24. Nakamura T, Shibata N, Nishimoto-Shibata T, et al. Regulation of SR-BI protein levels by phosphorylation of its associated protein, PDZK1. Proc Natl Acad Sci U S A 2005; 102:13404-13409.
25. Kocher O, Yesilaltay A, Cirovic C, et al. Targeted disruption of the PDZK1 gene in mice causes tissue-specific depletion of the high density lipoprotein receptor scavenger receptor class B type I and altered lipoprotein metabolism. J Biol Chem 2003; 278:52820-52825.
26. Svensson PA, Englund MC, Snackestrand MS, et al. Regulation and splicing of scavenger receptor class B type I in human macrophages and atherosclerotic plaques. BMC Cardiovasc Disord 2005; 5:25.
27. Trogan E, Feig JE, Dogan S, et al. Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. Proc Natl Acad Sci U S A 2006; 103:3781-3786.
28. Fuhrman B, Gantman A, Aviram M. Paraoxonase 1 (PON1) deficiency in mice is associated with reduced expression of macrophage SR-BI and consequently the loss of HDL cytoprotection against apoptosis. Atherosclerosis 2010; 211:61-68.
29. Han J, Nicholson AC, Zhou X, et al. Oxidized low density lipoprotein decreases macrophage expression of scavenger receptor B-I. J Biol Chem 2001; 276:16567-16572.
30. Wang N, Lan D, Chen W, et al. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci U S A 2004; 101:9774-9779.
31. Terasaka N, Wang N, Yvan-Charvet L, Tall AR. High-density lipoprotein protects macrophages from oxidized low-density lipoprotein-induced apoptosis by promoting efflux of 7-ketocholesterol via ABCG1. Proc Natl Acad Sci U S A 2007; 104:15093-15098.
32. Wang N, Ranalletta M, Matsuura F, et al. LXR-induced redistribution of ABCG1 to plasma membrane in macrophages enhances cholesterol mass efflux to HDL. Arterioscler Thromb Vasc Biol 2006; 26:1310-1316.
33. Sankaranarayanan S, Oram JF, Asztalos BF, et al. Effects of acceptor composition and mechanism of ABCG1-mediated cellular free cholesterol efflux. J Lipid Res 2009; 50:275-284.
34. Vaughan AM, Oram JF. ABCG1 redistributes cell cholesterol to domains removable by high density lipoprotein but not by lipid-depleted apolipoproteins. J Biol Chem 2005; 280:30150-30157
35. Kobayashi A, Takanezawa Y, Hirata T, et al. Efflux of sphingomyelin, cholesterol, and phosphatidylcholine by ABCG1. J Lipid Res 2006; 47:1791-1802.
36. Sano O, Kobayashi A, Nagao K, et al. Sphingomyelin-dependence of cholesterol efflux mediated by ABCG1. J Lipid Res 2007; 48:2377-2384.
37. Venkateswaran A, Repa JJ, Lobaccaro JM, et al. Human white/murine ABC8 mRNA levels are highly induced in lipid-loaded macrophages. A transcriptional role for specific oxysterols. J Biol Chem 2000; 275:14700-14707.
38. Schmitz G, Langmann T, Heimerl S. Role of ABCG1 and other ABCG family members in lipid metabolism. J Lipid Res 2001; 42:1513-1520.
39. Fu X, Menke JG, Chen Y, et al. 27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J Biol Chem 2001; 276:38378-38387.
40. Jakobsson T, Venteclef N, Toresson G, et al. GPS2 is required for cholesterol efflux by triggering histone demethylation, LXR recruitment, and coregulator assembly at the ABCG1 locus. Mol Cell 2009; 34:510-518.
41. Lorkowski S, Kratz M, Wenner C, et al. Expression of the ATP-binding cassette transporter gene ABCG1 (ABC8) in Tangier disease. Biochem Biophys Res Commun 2001; 283:821-830.
42. Nagelin MH, Srinivasan S, Lee J, et al. 12/15-Lipoxygenase activity increases the degradation of macrophage ATP-binding cassette transporter G1. Arterioscler Thromb Vasc Biol 2008; 28:1811-1819.
43. Yla-Herttuala S, Rosenfeld ME, Parthasarathy S, et al. Gene expression in macrophage-rich human atherosclerotic lesions. 15-lipoxygenase and acetyl low density lipoprotein receptor messenger RNA colocalize with oxidation specific lipid-protein adducts. J Clin Invest 1991; 87:1146-1152.
44. Nagelin MH, Srinivasan S, Nadler JL, Hedrick CC. Murine 12/15-lipoxygenase regulates ATP-binding cassette transporter G1 protein degradation through p38- and JNK2-dependent pathways. J Biol Chem 2009; 284:31303-31314.
45. Wang X, Liao D, Bharadwaj U, et al. C-reactive protein inhibits cholesterol efflux from human macrophage-derived foam cells. Arterioscler Thromb Vasc Biol 2008; 28:519-526.
46. Mauldin JP, Nagelin MH, Wojcik AJ, et al. Reduced expression of ATPbinding cassette transporter G1 increases cholesterol accumulation in macrophages of patients with type 2 diabetes mellitus. Circulation 2008; 117:2785-2792.
47. Mauerer R, Ebert S, Langmann T. High glucose, unsaturated and saturated fatty acids differentially regulate expression of ATP-binding cassette transporters ABCA1 and ABCG1 in human macrophages. Exp Mol Med 2009; 41:126-132.
48. Higgins CF. ABC transporters: from microorganisms to man. Annu Rev Cell Biol 1992; 8:67-113.
49. Yancey PG, Bielicki JK, Johnson WJ, et al. Efflux of cellular cholesterol and phospholipid to lipid-free apolipoproteins and class A amphipathic peptides. Biochemistry 1995; 34:7955-7965.
50. Santamarina-Fojo S, Remaley AT, Neufeld EB, Brewer HB Jr. Regulation and intracellular trafficking of the ABCA1 transporter. J Lipid Res 2001; 42:1339-1345. (Pubitemid 34007664)
51. Tamehiro N, Zhou S, Okuhira K, et al. SPTLC1 binds ABCA1 to negatively regulate trafficking and cholesterol efflux activity of the transporter. Biochemistry 2008; 47:6138-6147.
52. Singaraja RR, Kang MH, Vaid K, et al. Palmitoylation of ATP-binding cassette transporter A1 is essential for its trafficking and function. Circ Res 2009; 105:138-147
53. Linder MD, Mayranpaa MI, Peranen J, et al. Rab8 regulates ABCA1 cell surface expression and facilitates cholesterol efflux in primary human macrophages. Arterioscler Thromb Vasc Biol 2009; 29:883-888.
54. Wang N, Silver DL, Costet P, Tall AR. Specific binding of ApoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1. J Biol Chem 2000; 275:33053-33058.
55. Fitzgerald ML, Morris AL, Rhee JS, et al. Naturally occurring mutations in the largest extracellular loops of ABCA1 can disrupt its direct interaction with apolipoprotein A-I. J Biol Chem 2002; 277:33178-33187.
56. Vaughan AM, Oram JF. ABCA1 redistributes membrane cholesterol independent of apolipoprotein interactions. J Lipid Res 2003; 44:1373-1380.
57. Landry YD, Denis M, Nandi S, et al. ATP-binding cassette transporter A1 expression disrupts raft membrane microdomains through its ATPase-related functions. J Biol Chem 2006; 281:36091-36101.
58. Zarubica A, Plazzo AP, Stockl M, et al. Functional implications of the influence of ABCA1 on lipid microenvironment at the plasma membrane: a biophysical study. FASEB J 2009; 23:1775-1785.
59. Chambenoit O, Hamon Y, Marguet D, et al. Specific docking of apolipoprotein A-I at the cell surface requires a functional ABCA1 transporter. J Biol Chem 2001; 276:9955-9960.
60. Tang C, Vaughan AM, Anantharamaiah GM, Oram JF. Janus kinase 2 modulates the lipid-removing but not protein-stabilizing interactions of amphipathic helices with ABCA1. J Lipid Res 2006; 47:107-114.
61. Vedhachalam C, Duong PT, Nickel M, et al. Mechanism of ATP-binding cassette transporter A1-mediated cellular lipid efflux to apolipoprotein A-I and formation of high density lipoprotein particles. J Biol Chem 2007; 282:25123-25130.
62. Vedhachalam C, Ghering AB, Davidson WS, et al. ABCA1-induced cell surface binding sites for ApoA-I. Arterioscler Thromb Vasc Biol 2007; 27:1603-1609.
63. Vaughan AM, Tang C, Oram JF. ABCA1 mutants reveal an interdependency between lipid export function, apoA-I binding activity, and Janus kinase 2 activation. J Lipid Res 2009; 50:285-292.
64. Hassan HH, Bailey D, Lee DY, et al. Quantitative analysis of ABCA1- dependent compartmentalization and trafficking of apolipoprotein A-I: implications for determining cellular kinetics of nascent high density lipoprotein biogenesis. J Biol Chem 2008; 283:11164-11175.
65. Takahashi Y, Smith JD. Cholesterol efflux to apolipoprotein AI involves endocytosis and resecretion in a calcium-dependent pathway. Proc Natl Acad Sci U S A 1999; 96:11358-11363.
66. Denis M, Landry YD, Zha X. ATP-binding cassette A1-mediated lipidation of apolipoprotein A-I occurs at the plasma membrane and not in the endocytic compartments. J Biol Chem 2008; 283:16178-16186.
67. Faulkner LE, Panagotopulos SE, Johnson JD, et al. An analysis of the role of a retroendocytosis pathway in ABCA1-mediated cholesterol efflux from macrophages. J Lipid Res 2008; 49:1322-1332.
68. Lu R, Arakawa R, Ito-Osumi C, et al. ApoA-I facilitates ABCA1 recycle/ accumulation to cell surface by inhibiting its intracellular degradation and increases HDL generation. Arterioscler Thromb Vasc Biol 2008; 28:1820-1824.
69. Azuma Y, Takada M, Shin HW, et al. Retroendocytosis pathway of ABCA1/ apoA-I contributes to HDL formation. Genes Cells 2009; 14:191-204.
70. Miyazaki O, Kobayashi J, Fukamachi I, et al. A new sandwich enzyme immunoassay for measurement of plasma prebeta1-HDL levels. J Lipid Res 2000; 41:2083-2088.
71. Llera-Moya M, Drazul-Schrader D, Asztalos BF, et al. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol 2010; 30:796-801.
72. Pradel LC, Mitchell AJ, Zarubica A, et al. ATP-binding cassette transporter hallmarks tissue macrophages and modulates cytokine-triggered polarization programs. Eur J Immunol 2009; 39:2270-2280.
73. Schmitz G, Langmann T. Transcriptional regulatory networks in lipid metabolism control ABCA1 expression. Biochim Biophys Acta 2005; 1735:1-19.
74. Taylor JM, Borthwick F, Bartholomew C, Graham A. Overexpression of steroidogenic acute regulatory protein increases macrophage cholesterol efflux to apolipoprotein AI. Cardiovasc Res 2010; 86:526-534.
75. Hozoji M, Munehira Y, Ikeda Y, et al. Direct interaction of nuclear liver X receptor-beta with ABCA1 modulates cholesterol efflux. J Biol Chem 2008; 283:30057-30063.
76. Arakawa R, Yokoyama S. Helical apolipoproteins stabilize ATP-binding cassette transporter A1 by protecting it from thiol protease-mediated degradation. J Biol Chem 2002; 277:22426-22429.
77. Martinez LO, Agerholm-Larsen B, Wang N, et al. Phosphorylation of a pest sequence in ABCA1 promotes calpain degradation and is reversed by ApoAI. J Biol Chem 2003; 278:37368-37374. (Pubitemid 37175255)
78. Wang N, Chen W, Linsel-Nitschke P, et al. A PEST sequence in ABCA1 regulates degradation by calpain protease and stabilization of ABCA1 by apoA-I. J Clin Invest 2003; 111:99-107. (Pubitemid 36134853)
79. Iwamoto N, Lu R, Tanaka N, et al. Calmodulin interacts with ATP binding cassette transporter A1 to protect from calpain-mediated degradation and upregulates high-density lipoprotein generation. Arterioscler Thromb Vasc Biol 2010; 30:1446-1452.
80. Karwatsky J, Ma L, Dong F, Zha X. Cholesterol efflux to apoA-I in ABCA1- expressing cells is regulated by Ca2-dependent calcineurin signaling. J Lipid Res 2010; 51:1144-1156.
81. Okuhira K, Fitzgerald ML, Tamehiro N, et al. Binding of PDZ-RhoGEF to ATPbinding cassette transporter A1 (ABCA1) induces cholesterol efflux through RhoA activation and prevention of transporter degradation. J Biol Chem 2010; 285:16369-16377.
82. Lawn RM, Wade DP, Couse TL, Wilcox JN. Localization of human ATPbinding cassette transporter 1 (ABC1) in normal and atherosclerotic tissues. Arterioscler Thromb Vasc Biol 2001; 21:378-385.
83. Albrecht C, Soumian S, Amey JS, et al. ABCA1 expression in carotid atherosclerotic plaques. Stroke 2004; 35:2801-2806.
84. Brown AJ, Watts GF, Burnett JR, et al. Sterol 27-hydroxylase acts on 7-ketocholesterol in human atherosclerotic lesions and macrophages in culture. J Biol Chem 2000; 275:27627-27633.
85. Zhou X, He W, Huang Z, et al. Genetic deletion of low density lipoprotein receptor impairs sterol-induced mouse macrophage ABCA1 expression. A new SREBP1-dependent mechanism. J Biol Chem 2008; 283:2129-2138.
86. Teupser D, Kretzschmar D, Tennert C, et al. Effect of macrophage overexpression of murine liver X receptor-alpha (LXR-alpha) on atherosclerosis in LDL-receptor deficient mice. Arterioscler Thromb Vasc Biol 2008; 28:2009- 2015.
87. Feng B, Tabas I. ABCA1-mediated cholesterol efflux is defective in free cholesterol-loaded macrophages. Mechanism involves enhanced ABCA1 degradation in a process requiring full NPC1 activity. J Biol Chem 2002; 277:43271-43280.
88. Wang Y, Kurdi-Haidar B, Oram JF. LXR-mediated activation of macrophage stearoyl-CoA desaturase generates unsaturated fatty acids that destabilize ABCA1. J Lipid Res 2004; 45:972-980.
89. Wang Y, Oram JF. Unsaturated fatty acids phosphorylate and destabilize ABCA1 through a protein kinase C delta pathway. J Lipid Res 2007; 48:1062-1068.
90. Wang Y, Oram JF. Unsaturated fatty acids phosphorylate and destabilize ABCA1 through a phospholipase D2 pathway. J Biol Chem 2005; 280: 35896-35903.
91. Schneider JG, Yang Z, Chakravarthy MV, et al. Macrophage fatty acid synthase deficiency decreases diet-induced atherosclerosis. J Biol Chem 2010. [Epub ahead of print]
92. Kleemann R, Zadelaar S, Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res 2008; 79:360-376.
93. Jiang X, Zeng HS, Guo Y, et al. The expression of matrix metalloproteinases- 9, transforming growth factor-beta1 and transforming growth factor-beta receptor I in human atherosclerotic plaque and their relationship with plaque stability. Chin Med J (Engl) 2004; 117:1825-1829.
94. Hao XR, Cao DL, Hu YW, et al. IFN-gamma down-regulates ABCA1 expression by inhibiting LXRalpha in a JAK/STAT signaling pathway-dependent manner. Atherosclerosis 2009; 203:417-428.
95. Mei CL, Chen ZJ, Liao YH, et al. Interleukin-10 inhibits the down-regulation of ATP binding cassette transporter A1 by tumour necrosis factor-alpha in THP-macrophage-derived foam cells. Cell Biol Int 2007; 31:1456-1461.
96. Panousis CG, Evans G, Zuckerman SH. TGF-beta increases cholesterol efflux and ABC-1 expression in macrophage-derived foam cells: opposing the effects of IFN-gamma. J Lipid Res 2001; 42:856-863.
97. Han X, Kitamoto S, Wang H, Boisvert WA. Interleukin-10 overexpression in macrophages suppresses atherosclerosis in hyperlipidemic mice. FASEB J 2010. [Epub ahead of print]
98. Castrillo A, Joseph SB, Vaidya SA, et al. Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol Cell 2003; 12:805-816.
99. Chen S, Sorrentino R, Shimada K, et al. Chlamydia pneumoniae-induced foam cell formation requires MyD88-dependent and -independent signaling and is reciprocally modulated by liver X receptor activation. J Immunol 2008; 181:7186-7193.
100. Sorrentino R, Morello S, Chen S, et al. The activation of liver X receptors inhibits toll-like receptor-9-induced foam cell formation. J Cell Physiol 2010; 223:158-167.
101. Maitra U, Parks JS, Li L. An innate immunity signaling process suppresses macrophage ABCA1 expression through IRAK-1-mediated downregulation of retinoic acid receptor alpha and NFATc2. Mol Cell Biol 2009; 29:5989-5997.
102. Zhou X, Yin Z, Guo X, et al. Inhibition of ERK1/2 and activation of liver X receptor synergistically induce macrophage ABCA1 expression and cholesterol efflux. J Biol Chem 2010; 285:6316-6326
103. Marcil V, Delvin E, Sane AT, et al. Oxidative stress influences cholesterol efflux in THP-1 macrophages: role of ATP-binding cassette A1 and nuclear factors. Cardiovasc Res 2006; 72:473-482.
104. Semenza GL. HIF-1 and human disease: one highly involved factor. Genes Dev 2000; 14:1983-1991.
105. Semenza GL. Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends Mol Med 2001; 7:345-350.
106. Jiang BH, Rue E, Wang GL, et al. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 1996; 271:17771-17778.
107. Ugocsai P, Hohenstatt A, Paragh G, et al. HIF-1beta determines ABCA1 expression under hypoxia in human macrophages. Int J Biochem Cell Biol 2010; 42:241-252.
108. Hulten LM, Levin M. The role of hypoxia in atherosclerosis. Curr Opin Lipidol 2009; 20:409-414.
109. Tang C, Kanter JE, Bornfeldt KE, et al. Diabetes reduces the cholesterol exporter ABCA1 in mouse macrophages and kidneys. J Lipid Res 2010; 51:1719-1728.
110. Passarelli M, Tang C, McDonald TO, et al. Advanced glycation end product precursors impair ABCA1-dependent cholesterol removal from cells. Diabetes 2005; 54:2198-2205.
111. Brunham LR, Kruit JK, Pape TD, et al. Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med 2007; 13:340-347.
112. Vergeer M, Brunham LR, Koetsveld J, et al. Carriers of loss-of-function mutations in ABCA1 display pancreatic beta-cell dysfunction. Diabetes Care 2010; 33:869-874.
113. Tabas I, Tall A, Accili D. The impact of macrophage insulin resistance on advanced atherosclerotic plaque progression. Circ Res 2010; 106:58-67.
114. Adorni MP, Zimetti F, Billheimer JT, et al. The roles of different pathways in the release of cholesterol from macrophages. J Lipid Res 2007; 48:2453-2462.
115. Wang X, Collins HL, Ranalletta M, et al. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest 2007; 117:2216-2224.
116. Ye D, Meurs I, Ohigashi M, et al. Macrophage ABCA5 deficiency influences cellular cholesterol efflux and increases susceptibility to atherosclerosis in female LDLr knockout mice. Biochem Biophys ResCommun2010; 395:387-394.
117. Wang MD, Kiss RS, Franklin V, et al. Different cellular traffic of LDLcholesterol and acetylated LDL-cholesterol leads to distinct reverse cholesterol transport pathways. J Lipid Res 2007; 48:633-645.
118. Gelissen IC, Harris M, Rye KA, et al. ABCA1andABCG1synergize to mediate cholesterol export to apoA-I. Arterioscler Thromb Vasc Biol 2006; 26:534-540.
119. Out R, Jessup W, Le GW, et al. Coexistence of foam cells and hypocholesterolemia in mice lacking the ABC transporters A1 and G1. Circ Res 2008; 102:113-120.
120. Out R, Hoekstra M, Habets K, et al. Combined deletion of macrophage ABCA1 and ABCG1 leads to massive lipid accumulation in tissue macrophages and distinct atherosclerosis at relatively low plasma cholesterol levels. Arterioscler Thromb Vasc Biol 2008; 28:258-264.
121. Yvan-Charvet L, Ranalletta M, Wang N, et al. Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J Clin Invest 2007; 117:3900-3908.
122. Van EM, Bos IS, Hildebrand RB, et al. Dual role for scavenger receptor class B, type I on bone marrow-derived cells in atherosclerotic lesion development. Am J Pathol 2004; 165:785-794.
123. Yvan-Charvet L, Pagler TA, Wang N, et al. SR-BI inhibits ABCG1-stimulated net cholesterol efflux from cells to plasma HDL. J Lipid Res 2008; 49:107-114.
124. Covey SD, Krieger M, Wang W, et al. Scavenger receptor class B type Imediated protection against atherosclerosis in LDL receptor-negative mice involves its expression in bone marrow-derived cells. Arterioscler Thromb Vasc Biol 2003; 23:1589-1594.
125. Zhang W, Yancey PG, Su YR, et al. Inactivation of macrophage scavenger receptor class B type I promotes atherosclerotic lesion development in apolipoprotein E-deficient mice. Circulation 2003; 108:2258-2263.
126. Yancey PG, Jerome WG, Yu H, et al. Severely altered cholesterol homeostasis in macrophages lacking apoE and SR-BI. J Lipid Res 2007; 48:1140-1149.
127. Cuchel M, Lund-Katz S, Llera-Moya M, et al. Pathways by which reconstituted high-density lipoprotein mobilizes free cholesterol from whole body and from macrophages. Arterioscler Thromb Vasc Biol 2010; 30:526-532.
128. Yvan-Charvet L, Pagler T, Gautier EL, et al. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science 2010; 328:1689-1693.
129. Larrede S, Quinn CM, Jessup W, et al. Stimulation of cholesterol efflux by LXR agonists in cholesterol-loaded human macrophages is ABCA1-dependent but ABCG1-independent. Arterioscler Thromb Vasc Biol 2009; 29:1930-1936.
130. Despres JP, Lemieux I, Dagenais GR, et al. HDL-cholesterol as a marker of coronary heart disease risk: the Quebec cardiovascular study. Atherosclerosis 2000; 153:263-272.
131. Movva R, Rader DJ. Laboratory assessment of HDL heterogeneity and function. Clin Chem 2008; 54:788-800.
132. Tall AR. Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. J Intern Med 2008; 263:256-273.
133. Davidson WS, Silva RA, Chantepie S, et al. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler Thromb Vasc Biol 2009; 29:870-887
134. Smith JD. Dysfunctional HDL as a diagnostic and therapeutic target. Arterioscler Thromb Vasc Biol 2010; 30:151-155.
135. Feng H, Li XA. Dysfunctional high-density lipoprotein. Curr Opin Endocrinol Diabetes Obes 2009; 16:156-162.
136. Van der Westhuyzen DR, de Beer FC, Webb NR. HDL cholesterol transport during inflammation. Curr Opin Lipidol 2007; 18:147-151.
137. Jahanggiri A. High-density lipoprotein and the acute phase response. Curr Opin Endocrinol Diabetes Obes 2010; 17:156-160.
138. Mastorikou M, Mackness B, Liu Y, Mackness M. Glycation of paraoxonase-1 inhibits its activity and impairs the ability of high-density lipoprotein to metabolize membrane lipid hydroperoxides. Diabet Med 2008; 25:1049-1055.
139. Verges B. Lipid modification in type 2 diabetes: the role of LDL and HDL. Fundam Clin Pharmacol 2009; 23:681-685.
140. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 2009; 5:150-159.
141. Sugiyama S, Okada Y, Sukhova GK, et al. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol 2001; 158:879-891.
142. van Leeuwen M, Gijbels MJ, Duijvestijn A, et al. Accumulation of myeloperoxidase- positive neutrophils in atherosclerotic lesions in LDLR-/- mice. Arterioscler Thromb Vasc Biol 2008; 28:84-89.
143. Bergt C, Pennathur S, Fu X, et al. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci U S A 2004; 101:13032-13037.
144. Zheng L, Nukuna B, Brennan ML, et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 2004; 114:529-541.
145. Shao B, Tang C, Heinecke JW, Oram JF. Oxidation of apolipoprotein A-I by myeloperoxidase impairs the initial interactions with ABCA1 required for signaling and cholesterol export. J Lipid Res 2010; 51:1849-1858.
146. Undurti A, Huang Y, Lupica JA, et al. Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle. J Biol Chem 2009; 284:30825-30835.
147. Cavigiolio G, Geier EG, Shao B, et al. The exchange of apolipoprotein A-I between the lipid-associated and the lipid-free states: a potential target for oxidative generation of dysfunctional HDL. J Biol Chem 2010; 285:18847-18857.
148. Shao B, Cavigiolio G, Brot N, et al. Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-I. Proc Natl Acad Sci U S A 2008; 105:12224-12229.
149. Annema W, Nijstad N, Tolle M, et al. Myeloperoxidase and serum amyloid A contribute to impaired in vivo reverse cholesterol transport during the acute phase response but not group IIA secretory phospholipase A(2). J Lipid Res 2010; 51:743-754.
150. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 1991; 11:81-128.
151. Stadtman ER, Levine RL. Free radical-mediated oxidation of free amino acids and amino acid residues in proteins. Amino Acids 2003; 25:207-218.
152. Shao B, Pennathur S, Pagani I, et al. Dysfunctional HDL: modifying apolipoprotein A-I by malondialdehyde, but not by an array of other reactive carbonyls, blocks cholesterol efflux by the abca1 pathway. J Biol Chem 2010; 285:18473-18484.
153. Lindstedt L, Saarinen J, Kalkkinen N, et al. Matrix metalloproteinases-3, -7, and -12, but not -9, reduce high density lipoprotein-induced cholesterol efflux from human macrophage foam cells by truncation of the carboxyl terminus of apolipoprotein A-I. Parallel losses of pre-beta particles and the high affinity component of efflux. J Biol Chem 1999; 274:22627-22634.
154. Lindstedt L, Lee M, Oö rni K, et al. Cathepsins F and S block HDL3-induced cholesterol efflux from macrophage foam cells. Biochem Biophys Res Commun 2003; 312:1019-1024.
155. Lee M, von Eckardstein A, Lindstedt L, et al. Depletion of pre beta 1LpA1 and LpA4 particles by mast cell chymase reduces cholesterol efflux from macrophage foam cells induced by plasma. Arterioscler Thromb Vasc Biol 1999; 19:1066-1074.
156. Lee M, Sommerhoff CP, von Eckardstein A, et al. Mast cell tryptase degrades HDL and blocks its function as an acceptor of cellular cholesterol. Arterioscler Thromb Vasc Biol 2002; 22:2086-2091.
157. Kaartinen M, Penttilä A, Kovanen PT. Mast cells of two types differing in neutral protease composition in the human aortic intima. Demonstration of tryptase- and tryptase/chymase-containing mast cells in normal intimas, fatty streaks, and the shoulder region of atheromas. Arterioscler Thromb 1994; 14:966-972.
158. Judström I, Jukkola H, Metso J, et al. Mast cell-dependent proteolytic modification of HDL particles during anaphylactic shock in the mouse reduces their ability to induce cholesterol efflux from macrophage foam cells ex vivo. Atherosclerosis 2010; 208:148-154.